Clinical TrialsThe dosing of the first pregnant woman at high risk of FNAIT is viewed as a major milestone for Rallybio, as it signifies a significant undertaking and advancement in their study.
Financial OutlookRallybio ended 2024 with roughly $65.5M in cash, which is expected to provide a financial runway into the second half of 2026.
Product PotentialRLYB212 is viewed as a potential transformative option for mothers at risk of FNAIT, and a blockbuster opportunity with epidemiological data suggesting more than 30,000 at-risk pregnancies annually in the U.S. and EU.